Pharma News | Biotech News | Global Pharma

With exclusive access to key industry decision makers and best-in-class proprietary data, Scrip empowers you to understand the news behind the news.

How it helps

Use Scrip’s focus on the strategic implications of global pharma news to fully understand what worldwide developments in the industry mean for your business.

With end-to-end coverage encompassing the whole of the drug discovery, development, and product life cycle value chain, Scrip delivers analysis, news and insights across multiple therapy areas and product types.

How it works

Scrip provides business-critical market and company intelligence from our global network of analysts, journalists and key opinion leaders. They cover companies across the industry, from biotech start-ups to multinational giants such as Pfizer, Sanofi and Shire, and report on fields including cardiovascular, diabetes, dermatology, influenza, and oncology.

Scrip gives you access to the latest licensing opportunities, partnership deals, R&D activity, market access insights and company developments. Your subscription also includes the Scrip 100 annual review, which tracks and analyzes the performance of over 600 companies and provides additional insights into pharma industry topics that impact your business.

Request a free trial

Scrip

New Chugai CEO Lays Course As He Takes Reins

By Ian Haydock 25 May 2018

Chugai's new CEO Tatsuro Kosaka took up his position in March and is charged with taking the major Japanese company through the next stage of development as key products reach the global market and others begin to face biosimilar competition. In this first part of a two-part exclusive interview, he outlines the firm's vision, approach to R&D and how the strategic alliance with Roche is playing out.

Scrip

Remember When Provenge's Price Was Bold? Every New Cancer Drug In 2017 Cost $100,000 Or More

By Jessica Merrill 25 May 2018

The price of new oncology brands doubled in the US from 2013 to 2017, bringing the median annual price to more than $160,000 last year, up from $79,000 in 2013, according to a new IQVIA report. Spending on cancer drugs in the US has doubled since 2012, reaching nearly $50bn in 2017.

Scrip

Pfizer's Three-Pronged Oncology Strategy Includes Expanding Ibrance, Xtandi, Developing Blockbuster Combos

By Brenda Sandburg 23 May 2018

Xtandi use in early prostate cancer, lorlatinib as second-line treatment for non-small cell lung cancer and dacomitinib for first-line NSCLC have upcoming user fee dates.

Scrip

Missing In Action: China’s Best Shot In Ebola Vaccine Race

By Brian Yang 23 May 2018

As the Congo grapples with the latest outbreak of Ebola, China has approved its first domestically developed vaccine in record time, hailing it a national innovation champion. But as the World Health Organization starts vaccinations in Africa, can China make the cut and compete with global players including Merck & Co?

Scrip

Pharma Backs UK Parliament Report As 'No Deal Brexit' Fears Grow

18 May 2018

The pharmaceutical sector has given its backing to a report from MPs which warns that a no-deal Brexit will have a hugely damaging effect on the industry in the country, turning it into "a second-tier state for new and innovative medicines."

Scrip

Immuno Oncology: What To Watch At ASCO 2018

By Emily Hayes 18 May 2018

Cancer immunotherapy is once again set to dominate the upcoming American Society of Clinical Oncology annual meeting, with a continuing showdown for PD-1 inhibitors in lung cancer, a CAR-T battle, and disappointments for new IO classes.

Scrip

First Of Its Kind: Beam Seeks To Erase-And-Replace Single Letters In DNA's Alphabet

By Mandy Jackson 16 May 2018

Beam Therapeutics combines new insights from gene-editing pioneers to allow for single-letter editing of DNA and RNA. The company has raised $87m to develop DNA base-editing for therapies that in some diseases could be more efficient than CRISPR gene editing.

Scrip

NewLink CEO Reflects On Golden Age And Rapid Fall Of IDO

By Emily Hayes 16 May 2018

There is now a move back to the principle of doing randomized Phase II studies before jumping into Phase III, says CEO Chuck Link, as Roche's Genentech exits broad IDO/TDO deal.

Scrip

FDA Refuse-To-File Letter For Alkermes Depression Drug Suggests A Lengthy Commercial Delay

By Jessica Merrill 15 May 2018

CEO Richard Pops called FDA's letter for ALKS 5461 "surprising and troubling." Alkermes had been ramping up to launch the depression drug later this year, though some investors had remained skeptical.

Scrip

From Pharma Insider To Payer: Witty To Lead United's Optum

By Jessica Merrill 15 May 2018

Former GSK CEO Witty stood out among big pharma chief execs for his pessimistic outlook on US drug pricing, which shaped his diversification strategy at GSK. His experience as a pharma insider makes him an interesting choice to lead United's PBM and health services arm.

Scrip

GSK Gains Clarity For Pharma Focus Through Novartis Consumer JV Buy

By Mandy Jackson 15 May 2018

GSK removed some uncertainty about how much it could invest in pharma R&D and business development by purchasing Novartis' share of the firms' Consumer Healthcare Joint Venture. Now it can more accurately allocate capital as it prepares for battle in HIV and braces for Advair generics.

Scrip

IPO Update: Will Declining Returns Slow Fast Pace Of Biopharma Offerings?

By Mandy Jackson 15 May 2018

Offerings by Homology, Unum and Genprex at the end of March brought the first quarter's biopharma IPO total to 14 in the US, putting 2018 on track to beat the 2017 total of 42. But with the average return for this year's IPOs dropping, the pace of offerings could slow.

Scrip

Opdivos EU Colorectal Cancer is a Setback but More Than Offset By Potential Gains

By Ian Schofield 15 May 2018

Bristol-Myers Squibb has withdrawn its EU application to extend Opdivo’s use to metastatic colorectal cancer (mCRC), following a similar move for liver cancer last year. But the mCRC withdrawal is likely to have limited commercial impact and the company is more interested in pursuing the product’s use in combination treatment for this indication.

Scrip

Workforce Roundtable Part 1: Recruiting Biopharma Leaders As The Talent Pool Shrinks

By Mandy Jackson 15 May 2018

As Baby Boomers age out of the workforce, they'll be replaced in biopharma C-suites and boardrooms by a younger, more female and racially diverse group. A panel of current and former life science CEOs, venture investors and recruiters discuss the challenges and opportunities ahead.

Scrip

TVM Raises White Flag On Biovertis and Morphochem

By Mike Ward 15 May 2018

Denoive acquires from TVM Capital both Biovertis and Morphochem, plus a Phase II ready antibiotic asset, for an initial 4% stake worth €900,000. Since their formation, Biovertis and Morphochem have had more than $96m invested in them.